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Aim: This study aimed to describe the pattern of weight change in people with type 2 diabetes (T2DM) over time and when using alternative
treatment regimens.
Methods: Data were from routine clinical practice in the UK. The weight trend was determined for each year from 1995 to 2010 for both
prevalent and incident cases. Baseline weight was compared to absolute (mean ) and relative weights (% ) at 6, 12 and 24 months.
Results: Mean, standardized weight, in prevalent cases increased from 83.4 to 92.1 kg for males and from 73.5 to 79.9 kg for females
between 1995 and 2010 (p < 0.0001). For incident cases, the respective ﬁgures were 86.7 to 93.6 kg for males and 76.0 to 80.7 kg (p <
0.0001) for females. Between baseline and 6, 12 and 24 months, there were signiﬁcant changes in weight for the majority of the treatment
regimens selected for analysis. The largest weight increase at 12 months was for the patients who were prescribed a combination therapy with
insulin and a thiazolidinedione, with a median increase of 4.1 kg (95% CI −0.60 to 8.0, p < 0.001). The largest weight decrease at 12 months
was for the patients who were prescribed a combination therapy of metformin and exenatide, with a median decrease of −7.0 kg (95% CI
−12.0 to −2.0, p < 0.001).
Conclusions: There was a continual increase in body weight in people with T2DM over time, and considerable differences in the impact on
weight using alternative treatment regimens. At the same time, glycaemic control remained relatively unchanged.
Keywords: antidiabetic drugs, obesity, secular trends, type 2 diabetes, weight change
Date submitted 19 September 2011; date of first decision 21 November 2011; date of final acceptance 21 November 2011
Introduction
Type 2 diabetes (T2DM) is a chronic condition characterized by
excess micro- and macrovascular morbidity and mortality [1].
Hyperglycaemia is a risk factor for these complications and,
therefore, the attainment of near-normal glycaemia is a
major therapeutic target for people with the disease [2]. The
benefits of sustained glycaemic control have been shown
in the United Kingdom Prospective Diabetes Study, which
found that a 0.9% decrease in haemoglobin A1c (HbA1c)
in the intensive treatment group, was associated with a 25%
reduction inmicrovascular complicationswhen comparedwith
conventional treatment [3].
Where lifestyle modification has failed to result in
appropriate glycaemic control, metformin is now universally
recommended as the first-line treatment for patients with
T2DM. However, therapy failure occurs within 3 years in over
40% of patients on metformin alone [4], resulting in the need
for multiple oral antidiabetes agents (OADs) and, eventually,
insulin.
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Pharmacotherapy aiming at normal glycaemia may be asso-
ciated with an increased risk of hypoglycaemia and weight
gain. Increasing weight is of particular concern because more
than 80% of the T2DM population are overweight or obese
at diagnosis [5], set against a background of increasing obe-
sity in the general population [6,7]. For people with diabetes,
obesity may not only increase cardiovascular risk but may also
have a detrimental impact on health-related quality of life,
treatment adherence and treatment cost-effectiveness [8,9].
Many glucose-lowering therapies, including insulin, sulpho-
nylurea and the thiazolidinediones [(TZDs), or glitazones],
are associated with weight gain [8–11]. Conversely, metformin
and the newer, incretin-mimetic therapies—the GLP-1 ana-
logues (exenatide and liraglutide) [12] and the dipeptidyl
peptidase (DPP)-4 inhibitors (sitagliptin, vildagliptin and
saxagliptin) [13]—are associated with weight loss or weight
neutrality,whichmay translate into improvedoutcomes [9,14].
In this study, we aimed to characterize the secular weight
pattern for people with T2DM and, in particular, to evaluate
weight change associated with different diabetes treatment
regimens, using data from routine clinical practice. In
order to place these data in the context of corresponding
clinical outcome, we also characterized the pattern of glucose
control (HbA1c) in relation to body weight changes as a
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function of different glucose-lowering therapeutic regimens.
For completeness, we also include reference weight data from
the non-diabetic population.
Methods
Ethics Statement
The General Practice Research Database Group has obtained
ethical approval from a multicentre research ethics committee
for all observational research that does not involve patient
involvement. Approval for this particular study was awarded
by its Independent Scientific Advisory Committee, reference
11_004.
Data Source
Data were extracted from the General Practice Research
Database (GPRD) [15], a longitudinal, anonymized data set
derived from over 350 primary care practices in the UK.
It contains records for approximately 10 million patients,
of whom approximately 5 million are actively registered.
Available data include patient demographics, medical history,
test results and prescriptions. Ethnicity is not recorded for
individual patients and is therefore not included in our study.
Diagnostic information in GPRD is recorded using the Read
Code classification.
Patient Selection and Coding of Diabetes Type
All patients included in the cohort were registered with a
general practice contributing to the GPRD dataset. Patients
were extracted with a Read Code indicative of diabetes. As not
all Read Codes for diabetes differentiate between type 1 and
type 2, and some patient histories may erroneously contain
codes for both types, patients with T2DM were defined by one
or more of the following:
1. Read Codes exclusively indicative of T2DM
2. Prescription of two classes of OAD
3. A Read Code indicative of T2DM (regardless of others
indicative of type 1 or non-specific diabetes) and a
prescription for an OAD
Patients were defined as incident cases if they had a minimum
of 180 days between registration at the practice and their
presentation with diabetes, defined as the earlier of first
diagnosis or first prescription of a diabetes medication.
Baseline Characteristics
Baseline date was defined as that on which the treatment
regimen was initiated. Baseline weight was defined as the
nearest weight measurement recorded prior to baseline date
to a maximum of −180 days. Other baseline characteristics
(HbA1c, systolic and diastolic blood pressure, cholesterol,
high density lipids, low density lipids and triglycerides) were
determined as the value nearest to baseline in the preceding
30 days. If no value was recorded, the nearest value to baseline
in the subsequent 30 days was recorded. If again no value was
recorded, the nearest value in the year prior to baseline was
used.
Secular Trends in Weight
The secular trend of weight was analysed for patients with and
without T2DM and plotted for each year from 1995 to 2010,
inclusively. The first weight value recorded per patient per year
was used. Annual mean weights were standardized by age to
the population profile for 2010 and presented by sex. Age- and
sex-specific weight profiles were also calculated for 2000 and
2010.
Diabetes-speciﬁc Treatment Regimens
Treatments were considered in the following categories: (i)
exenatide, (ii) DPP-4 inhibitors, (iii) insulin, (iv) metformin,
(v) TZDs, (vi) sulphonylurea and (vii) other OADs.
Patients were defined by treatment cohorts based on the
criteria of a minimum duration of 180 days on the same
therapy combination and a ‘‘wash-in’’ period of at least 90 days
between the patients’ registering at the practice and their first
relevant prescription.
Outcome Measurement
Weight change was measured from baseline to 6, 12 and
24 months (±90 days) both as an absolute change in kilograms
and as percentage change, and compared using the Wilcoxon
signed rank test. For specific regimens, a rolling 30-day average
weight, indexed to baseline, was presented. We also evaluated
the mean HbA1c for a limited number of regimens by year, for
the study period.
Results
Secular Trends in Weight
For patients with T2DM, 1 822 790 weight measurements were
included in the secular trend analysis, ranging from 38 408
in 1995 to 184 474 in 2010. For the prevalent cohort, mean
standardized weight increased from 83.4 to 92.1 kg for males
and from 73.5 to 79.9 kg for females (figure 1). For incident
cases, the figures were 86.7 to 93.6 kg for males and 76.0 to
80.7 kg for females.
For reference purposes, for the population as a whole aged
≥35 years, corresponding data were available for 4 088 482
people without diabetes. Here, mean standardized weight
increased over the study period from 80.3 to 86.7 kg for males
and from 67.2 to 72.5 kg for females (figure 1).
Study Subjects and Baseline Characteristics
Baseline characteristics for the T2DM cohorts in 2000 and
2010, presented by 2010 weight quartiles, are shown in Table 1.
In both cohorts, mean age was lower in relation to increasing
weight, while there was a slight increase in mean HbA1c.
Comparison between the cohorts showed an improved profile
in 2010 in terms of HbA1c, total cholesterol, lipids and blood
pressure.
There were 32 therapy regimens with frequencies greater
than 100. The total number of valid therapy periods was
240 307. Of these patients, 149 004 (62.0%), 133 298 (55.5%)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
2 Morgan et al. Volume 0 No. 0 2012
DIABETES, OBESITY AND METABOLISM original article
Figure 1. Secular trend for age-standardized, mean weight for people with prevalent and incident diabetes and for people without diabetes. DM, diabetes
mellitus; ND, non-diabetic.
Table 1. Baseline characteristics by weight quartile of patients with diabetes in 2000 and 2010.
Year 2000 2010
Weight quartile∗ (Kg) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
n 21 860 — 19 923 — 16 914 11 495 — —
Age—years (s.d.) 67.3 (15.2) 64.8 (13.3) 62.1 (12.2) 57.2 (11.9) 69.9 (14.3) 66.9 (12.8) 64.2 (12.1) 59.9 (11.4)
Females—% 67.1 39.8 32.5 28.7 68.1 43.8 33.4 29.3
Systolic BP—mmHg (s.d.) 143.9 (22.6) 145.2 (20.9) 146.0 (20.0) 147.0 (19.4) 134.7 (19.0) 136.2 (17.6) 136.8 (17.0) 138.1 (16.8)
Diastolic BP—mmHg (s.d.) 78.6 (10.6) 80.7 (10.4) 82.7 (10.4) 85.4 (10.5) 74.0 (10.5) 76.0 (10.3) 77.5 (10.3) 79.9 (10.5)
HbA1c—% (s.d.) 7.9 (1.9) 7.9 (1.8) 8.0 (1.8) 8.1 (1.8) 7.2 (1.6) 7.4 (1.6) 7.4 (1.6) 7.6 (1.7)
Total cholesterol—mmol/l
(s.d.)
5.4 (1.2) 5.4 (1.1) 5.3 (1.1) 5.3 (1.1) 4.5 (1.1) 4.3 (1.1) 4.3 (1.1) 4.3 (1.1)
HDL—mmol/l (s.d.) 3.2 (1.0) 3.2 (0.9) 3.2 (0.9) 3.1 (0.9) 2.4 (0.9) 2.4 (0.9) 2.4 (0.9) 2.3 (0.9)
LDL—mmol/l (s.d.) 1.4 (0.5) 1.3 (0.4) 1.2 (0.3) 1.1 (0.3) 1.4 (0.4) 1.3 (0.4) 1.2 (0.4) 1.1 (0.3)
Triglycerides—mmol/l (s.d.) 1.9 (1.1) 2.1 (1.2) 2.4 (1.2) 2.6 (1.3) 1.5 (0.8) 1.7 (0.9) 1.8 (1.0) 2.0 (1.0)
GP contacts preceding
year—mean n (s.d.)AQ2
11.3 (9.7) 11.0 (9.4) 11.1 (9.5) 11.3 (10.2) 15.0 (12.8) 14.3 (12.0) 14.1 (11.7) 14.7 (12.4)
BP, blood pressure; GP, general practice; HbA1c, haemoglobin A1c; s.d., standard deviation.
∗Quartiles in 2010—Q1: ≤ 72.0.3 kg; Q2: >; 72.0.3 ≤ 8.10; Q3: > 84.1 ≤ 98.0; Q4: > 98.0.
and 85 925 (35.8%) had weight measurements at circa 180, 365
and 730 days, respectively. The most common regimen was
metformin monotherapy with 80 160 observations. Baseline
characteristics by regimen are shown in Table 2.
Absolute Weight Change
Absolute changes in weight for the 32 therapy combinations
at 6, 12 and 24 months are shown in Table 3. At each
time point, there were significant changes in weight for the
majority of regimens. For the patients who were prescribed the
most common regimen, metformin monotherapy, there was a
median average reduction in weight of −1.0 kg [inter-quartile
range (IQR) −4.1 to 1.6 kg, p < 0.001] at 6 months, −1.1 kg
(IQR−4.6 to 2.0 kg, p< 0.001) at 12 months and−1.5 kg (IQR
−5.0 to 2.0 kg, p < 0.001) at 24 months. Insulin monotherapy
was associated with an average weight gain of 2.1 kg (IQR −0.9
to 5.9 kg, p< 0.001) at 6 months, 3.4 kg (IQR 0.0 to 7.6 kg, p<
0.001) at 12 months and 4.5 kg (IQR 0.0 to 9.0 kg, p < 0.001)
at 24 months.
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At 6 months, the largest weight increase was associated with
the patients who were prescribed a combination therapy of
metformin, insulin, sulphonylurea and TZDs, with a median
increase of 2.6 kg (IQR −0.25 to 6.0 kg, p < 0.001). The largest
reduction was for the patients who were prescribedmetformin,
insulin and exenatide, with a median reduction of −5.0 kg
(IQR −8.65 to −0.8 kg, p < 0.001).
The largest weight increase at 12 months was for the patients
whowereprescribeda combination therapyof insulin andTZD,
with a median increase of 4.1 kg (IQR −0.60 to 8.0 kg, p <
0.001). The largest weight decrease at 12 months was associated
with the patients who were prescribed a combination therapy
ofmetformin and exenatide, with amedian decrease of−7.0 kg
(IQR −12.0 to −2.0 kg, p < 0.001).
At 24 months, the largest weight increase was for patients
treated with metformin, insulin, sulphonylurea and TZD, with
an increase of 6.0 kg (IQR 2.0 to 9.6 kg, p < 0.001). The largest
decreasewas for patients treatedwithmetformin and exenatide:
−8.7 kg (IQR −12.5 to −2.9 kg, p < 0.001).
Relative Weight Change
Relative weight change is shown in Table 3. In general, these
reflected the patterns observed in absolute change. At 6 months
the largest weight increase was associated with a combination
therapy of metformin, sulphonylurea, insulin and TZD, with
an increase of 3.0% (IQR −0.4 to 6.9%, p< 0.001). The largest
reduction in weight was for metformin, insulin and exenatide,
with a reduction of −4.5% (IQR −8.1 to −0.7%, p < 0.001).
The largest weight increase at 12 months was for metformin,
sulphonylurea, insulin and TZD with an increase of 4.6%
(IQR −0.3 to 7.0%, p < 0.001). The largest weight decrease
at 12 months was associated with a combination therapy of
metformin and exenatide, with a decrease of −6.1% (IQR
−10.9 to −1.8%, p < 0.001).
At 24 months the largest weight increase was for metformin,
sulphonylurea, insulin and TZD, with an increase of 6.25%
(IQR 2.4 to 10.75%, p < 0.001). The largest decrease was
for metformin and exenatide: −7.8% (IQR −11.4 to −2.2%,
p < 0.001).
Rolling Mean Weight by Treatment Regimen
Figure 2 shows the rolling weight average for insulin,
metformin and sulphonylurea monotherapies; metformin and
sulphonylurea combination therapy; and any combination
including DPP-4 inhibitors or exenatide. Both the insulin
and sulphonylurea monotherapies and the metformin plus
sulphonylurea therapy showed a consistent weight increase
from baseline.Metforminmonotherapy was associated with an
initial gain followed by a decrease. Both the DPP-4 inhibitors
and exenatide showed a general downward trend.
Glucose Control—HbA1c
Over the corresponding period, mean HbA1c for patients
treated with insulin remained at 8.3%. For metformin, this fell
from 7.7 to 7.1%; for metformin and sulphonylurea combined,
it fell from 8.3 to 7.6%; and for sulphonylurea, it fell from
7.7 to 7.2%.
Figure 2. Sixty-day rolling average of weight for specific regimens from
baseline to 18 months. AQ4
Discussion
There was a continual increase in average weight for all patients
and for the subset of patients with T2DM between 1995 and
2010. For those without diabetes, there was an increase inmean
weight of 6.3 and 6.4 kg for males and females, respectively.
This was greater than the 5.1 and 3.4-kg observed in the
Health Survey for England for the same demographic group,
but inclusive of those with diabetes [16]. For T2DM, after
standardization for age, this increase was approximately 8.6 kg
for males and 6.3 kg for females. While we adjusted for age
and sex, it is possible that there may be other differences in
the cohorts at different time points. For example, the increased
emphasis on targeted screening for diabetes has led to the
identification of a less morbid population with T2DM [17]. As
body mass index is recommended as a filtering variable for
screening [18], it is likely that this will be reflected in the profile
of newly diagnosed cases. However, the pattern was consistent
over time rather than the sudden change that one would expect
if screening were influential.
The secular increase in weight may have significant clinical
consequences. To place the weight changes evident in this study
into context, the average reduction in weight at 2 years using
the antiobesity drug orlistat (120 mg) is around 6 kg (3.5 kg
vs. placebo) and slightly less at the lower dose [19]. If the
health benefits of weight loss claimed for such medications
are justifiable, common sense dictates that there must be
inverse consequences related to weight gain on diabetes-
related drugs. Weight gain in people with T2DM is associated
with reduced treatment adherence and health-related quality
of life [8,9]. Furthermore, weight gain may further heighten
the cardiovascular risk characteristic of T2DM [20]. A recent
population-based cohort study has, however, showed a normal
life expectancy in subjects with T2DM in primary care when
compared to the general population, which may reflect the
impact of multiple-risk-factor intervention in people with
T2DM [21].
As expected, alternative treatment regimens were associated
with differing patterns of weight change, with the greatest
increase in weight being associated with the complex
and unusual combination therapy of metformin, insulin,
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sulphonylurea and TZD. Weight loss was most pronounced in
people treatedwithmetforminplus exenatide, othermetformin
combinations and regimens including exenatide and the DPP-
4 inhibitors. The analysis broadly confirmed clinical trial
experience, with regimens involving metformin, exenatide and
the DPP-4-inhibitors associated with weight loss, and insulin,
sulphonylurea and the TZDs associated with weight gain.
When treatments with different weight properties were used
in combination therapy, a modifying effect was observed. For
example, while at 24 months, insulin was associated with a
median increase of 4.5 kg and metformin with a decrease of
1.5 kg; in combination, there was an overall increase of only
2.4 kg. Consequently, when developing therapeutic strategies
for individual patients, the interaction of individual agents with
respect to weight should be considered.
There were study limitations. Weight was not collected
at precise times and we therefore lost patients who did not
have a valid weight measurement within prespecified time
frames. Patients who were frequently monitored for weight
were therefore more likely to be included in our cohort.
The progressive increase in weight observed in the T2DM
cohort may be partly accounted for by the increase in
obesity throughout society, in general [6,7]. However, the
introduction of evermore stringent glycaemic targets [1] and
the implementationof theQuality andOutcomesFramework in
the UK in 2004 [22] with its target-driven payment structure,
along with clinical trial data advocating intensive glycaemic
control [23], may have resulted in increased prescribing
of glucose-lowering therapies [22]. Such considerations may
contribute to the secular pattern of weight gain seen in
this analysis. Furthermore, hypoglycaemia, a recognized
consequence of intensified glycaemic control, particularly
with sulphonylurea and insulin therapy [24], often results in
defensive eating further contributing to weight gain. Indeed,
therapeutic approaches resulting in a lowriskof hypoglycaemia,
such as metformin, DPP-4 inhibitors and exenatide [14], were
associated with modest secular downward trends in weight,
while the greatest reduction was noted with metformin plus
exenatide combination therapy, suggesting that the optimum
clinical utility of GLP-1 analogues may be obtained in
combination with metformin.
These observations and others [23] raise important ques-
tions relating to current therapeutic approaches to manag-
ing glycaemia. Treatment costs for T2DM in the UK have
almost doubled between 1997 and 2007 [23], largely driven
by increased prescription costs. During this period there has
been no improvement in overall glycaemic control [23]. The
relationship between weight gain and glycaemic control over
this period may represent both cause and effect, with increased
use of hypoglycaemic therapies contributing to weight gain and
weight gain representing a barrier to the improvement of gly-
caemic control. From the public health perspective, therefore,
it may be more pertinent to focus resources not on pharma-
cotherapy, but on the promotion of lifestyle modification to
reduce the incident risk of T2DM and to reduce weight in
people with established T2DM. Furthermore, intensification of
glycaemic control has not been shown to reduce all-cause mor-
tality in people with T2DM—and may even result in adverse
outcomes [25]—and this, coupled with the observations from
our analysis, supports the need to develop and implement an
individualized therapeutic approach.
Not only is the UK population in general continuously
increasing in weight—thus adding to the burden of
T2DM—but also those with T2DM are continuously
increasing in weight. At a population level, there is depressingly
little evidence that any treatment regimen is impacting upon
what is conventionally the primary purpose of diabetes-related
treatment, that is, glucose control.
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